Advancements in CRISPR technology: Unveiling novel horizons in genome editing.

Huiz. A. Kamoun*

Department of Genomic Medicine, Weill Cornell Medicine, New York, USA

Received: *27-Oct-2023, Manuscript No. RNAI-23-123003;* **Editor assigned:** *31-Oct-2023, Pre QC No. RNAI-23-123003 (PQ);* **Reviewed:** *14-Nov-2023, QC No. RNAI-23-123003;* **Revised:** *21-Nov-2023, Manuscript No. RNAI-23-123003 (R);* **Published:** *29-Nov-2023, DOI:10.35841/2591-7781.19.1000166*

Description

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized the field of genetic engineering, offering unprecedented precision and efficiency in genome editing. From base editing to prime editing, this review encompasses the latest breakthroughs that propel *CRISPR*. The introduction sets the stage by highlighting the transformative impact of *CRISPR* technology on genetic engineering. It briefly outlines the historical context, emphasizing the need for precise and efficient genome-editing tools. The brief overview of the historical development of CRISPR technology, starting from its discovery in bacteria to its adaptation as a powerful genome-editing tool. Emphasis is placed on the transformative nature of CRISPR in genetic research and biotechnology [1].

Base editing and prime editing are two notable advancements in CRISPR technology. Base editing enables precise changes to single DNA letters without causing double-strand breaks, reducing the risk of errors introduced during repair. Prime editing, on the other hand, offers even greater precision by directly rewriting the target DNA without requiring a donor DNA template. The focus is on the CRISPR-associated protein (Cas) and guide RNA (gRNA) components, elucidating the mechanism of target DNA recognition and cleavage. An update on recent breakthroughs and advancements in CRISPR technology, including base editing, prime editing, and other innovations that enhance precision, efficiency, and minimize off-target effects. It also discusses the challenges and ongoing efforts to overcome them [2,3].

The versatility of CRISPR technology is explored through its diverse applications. This section covers gene knockout for functional studies, gene knock-in for therapeutic purposes, and gene drive systems for altering entire populations. Case studies and examples of successful applications in various organisms are highlighted to underscore the broad impact of CRISPR technology. The diverse applications of CRISPR technology across various fields. Subsections may include: Discusses the targeted modification of genes for therapeutic, agricultural, or research purposes. Explores the use of CRISPR for understanding gene function, gene regulation, and the identification of essential genes. Highlights how CRISPR enables the creation of accurate disease models for studying pathogenesis and potential treatments [4-6].

Examines the promising role of CRISPR in developing targeted therapies for genetic disorders. An in-depth discussion on how these techniques enhance precision, reduce off-target effects, and expand the scope of genetic modifications is provided. This section also introduces the concept of CRISPR interference (CRISPRi) and its potential applications. Ethical concerns surrounding CRISPR technology are addressed, including the potential for unintended consequences, off-target effects, and the ethical implications of germline editing. The outlining potential future directions for CRISPR technology. This includes advancements in delivery methods, increasing the specificity of editing tools, and exploring new applications in areas such as synthetic biology and gene therapy [7-9].

The conclusion summarizes key findings and emphasizes the continuous evolution of CRISPR technology. It calls for ongoing collaboration between scientists, ethicists, and policymakers to ensure responsible and ethical use of this powerful genetic tool. While Cas9 is the most well-known enzyme used in CRISPR systems, researchers have been exploring other Cas proteins with unique properties. For example, *Cas12* and *Cas13* have been studied for their ability to target RNA, providing new possibilities for gene regulation and antiviral applications [10,11].

References

1. Moshous D, Callebaut I, Chasseval R, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency.Cell2001; 105: 177-86.
2. Gao Y, Ferguson DO, Xie W, et al. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development.Nature2000; 404(6780): 897-900.
3. Song J, Yang D, Xu J, et al. RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency.Nat Commun2016; 7: 10548.
4. Chu VT, Weber T, Weferse B, et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells.Nat Biotechnol2015; 33(5): 543-48.
5. Maruyama T, Dougan SK, Truttmann MC, et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining.Nat. Biotechnol.2015; 33: 538-42.
6. Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice.Mol Cell 2012; 47(4): 497-510.

Citation: *Kamoun HA. Advancements in CRISPR technology: Unveiling novel horizons in genome editing. J RNA Genomics 2023;19(5):1-2.*

7. Shrivastav M, Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice.Cell Res2008; 18(1): 134-47.
8. Dong L, Guan X, Li N, et al. An anti-CRISPR protein disables type V Cas12a by acetylation.Nat. Struct. Mol Biol2019; 26(4): 308-14.
9. Suresh B, Ramakrishna S, Kim H. Cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA for genome editing.Methods Mol Biol2017; 1507: 81-94.
10. Slaymaker IM, Gao L, Zetsche B, et al. Rationally engineered Cas9 nucleases with improved specificity. Science2015; 351(6268): 84-8.
11. Kiani S, Beal J, Ebrahimkhani MR, et al. CRISPR transcriptional repression devices and layered circuits in mammalian cells.Nat Methods2014; 11(7): 723-6.

***Correspondence to:**

Huiz. A. Kamoun

Department of Genomic Medicine,

Weill Cornell Medicine,

New York, USA

E-mail: huizakamoun8@gmail.com